Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.64
TBIO's Cash to Debt is ranked lower than
51% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. TBIO: 0.64 )
TBIO' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.64

Equity to Asset 0.29
TBIO's Equity to Asset is ranked lower than
51% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TBIO: 0.29 )
TBIO' s 10-Year Equity to Asset Range
Min: -0.46   Max: 0.95
Current: 0.29

-0.46
0.95
F-Score: 2
Z-Score: -7.30
M-Score: -2.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -60.08
TBIO's Operating margin (%) is ranked higher than
58% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. TBIO: -60.08 )
TBIO' s 10-Year Operating margin (%) Range
Min: -63.96   Max: -1.53
Current: -60.08

-63.96
-1.53
Net-margin (%) -46.83
TBIO's Net-margin (%) is ranked higher than
59% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. TBIO: -46.83 )
TBIO' s 10-Year Net-margin (%) Range
Min: -136.16   Max: -2.06
Current: -46.83

-136.16
-2.06
ROE (%) -124.40
TBIO's ROE (%) is ranked higher than
50% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. TBIO: -124.40 )
TBIO' s 10-Year ROE (%) Range
Min: -154.92   Max: -3.63
Current: -124.4

-154.92
-3.63
ROA (%) -40.75
TBIO's ROA (%) is ranked higher than
55% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. TBIO: -40.75 )
TBIO' s 10-Year ROA (%) Range
Min: -72.54   Max: -2.7
Current: -40.75

-72.54
-2.7
ROC (Joel Greenblatt) (%) -372.68
TBIO's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. TBIO: -372.68 )
TBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -534.55   Max: -4.92
Current: -372.68

-534.55
-4.92
Revenue Growth (3Y)(%) -22.50
TBIO's Revenue Growth (3Y)(%) is ranked higher than
56% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. TBIO: -22.50 )
TBIO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.5   Max: 9.9
Current: -22.5

-23.5
9.9
EBITDA Growth (3Y)(%) -4.70
TBIO's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. TBIO: -4.70 )
TBIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.7   Max: 71
Current: -4.7

-54.7
71
EPS Growth (3Y)(%) -8.50
TBIO's EPS Growth (3Y)(%) is ranked higher than
70% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. TBIO: -8.50 )
TBIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.5   Max: 179.5
Current: -8.5

-58.5
179.5
» TBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.85
TBIO's P/B is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. TBIO: 1.85 )
TBIO' s 10-Year P/B Range
Min: 0.97   Max: 704
Current: 1.85

0.97
704
P/S 0.45
TBIO's P/S is ranked higher than
97% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. TBIO: 0.45 )
TBIO' s 10-Year P/S Range
Min: 0.4   Max: 3.51
Current: 0.45

0.4
3.51
Current Ratio 1.65
TBIO's Current Ratio is ranked higher than
52% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. TBIO: 1.65 )
TBIO' s 10-Year Current Ratio Range
Min: 0.96   Max: 18.01
Current: 1.65

0.96
18.01
Quick Ratio 1.38
TBIO's Quick Ratio is ranked higher than
50% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. TBIO: 1.38 )
TBIO' s 10-Year Quick Ratio Range
Min: 0.67   Max: 17.35
Current: 1.38

0.67
17.35
Days Inventory 75.12
TBIO's Days Inventory is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. TBIO: 75.12 )
TBIO' s 10-Year Days Inventory Range
Min: 73.18   Max: 369.56
Current: 75.12

73.18
369.56
Days Sales Outstanding 111.39
TBIO's Days Sales Outstanding is ranked higher than
63% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. TBIO: 111.39 )
TBIO' s 10-Year Days Sales Outstanding Range
Min: 66.74   Max: 152.44
Current: 111.39

66.74
152.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.36
TBIO's Price/Median PS Value is ranked higher than
99% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. TBIO: 0.36 )
TBIO' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 13.72
Current: 0.36

0.33
13.72
Earnings Yield (Greenblatt) -80.00
TBIO's Earnings Yield (Greenblatt) is ranked lower than
66% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. TBIO: -80.00 )
TBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 20.7   Max: 39
Current: -80

20.7
39

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Transgenomic Inc was incorporated in Delaware on March 6, 1997. The Company is a biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. Its operations are organized and reviewed by management along its product lines and presented in the following two complementary business segments: Laboratory Services and Genetic Assays and Platform. In Laboratory Services: its laboratories specialize in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Its Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment ("CLIA") as high complexity laboratories and its Omaha facility is also accredited by the College of American Pathologists ("CAP"). Its laboratories employ genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA ("cfDNA") and circulating tumor cells ("CTCs") at levels greater than 1,000-fold higher than standard DNA sequencing techniques. In enetic Assays and Platforms: its proprietary product is the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bioinstruments produced by other manufacturers ("OEM Equipment") through its sales and distribution network. The Company also distributes bioinstruments produced by other manufacturers ('OEM Equipment') through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by its technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. It develops, manufactures and sells these consumable products. In addition, it manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Competitors in these areas, among others, include Applied Biosystems, Qiagen, Roche, Sequenom and Illumina. Competition for some of its non-WAVE consumable products comes from numerous well-diversified life sciences reagent providers, including, among others, Invitrogen, Qiagen, Roche, Stratagene and Promega. The Company is subject to a variety of federal, state and municipal environmental and safety laws based on its use of hazardous materials in both manufacturing and research and development operations.
» More Articles for TBIO

Headlines

Articles On GuruFocus.com
Transgenomic, Inc. Reports Second Quarter 2009 Results Aug 12 2009 

More From Other Websites
TRANSGENOMIC INC Financials May 22 2015
10-Q for Transgenomic, Inc. May 16 2015
Transgenomic Reports First Quarter 2015 Financial Results - Conference Call to be Held at 5:00 PM... May 14 2015
TRANSGENOMIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 14 2015
Transgenomic Reports First Quarter 2015 Financial Results May 14 2015
Q1 2015 Transgenomic Inc Earnings Release - After Market Close May 14 2015
Transgenomic to Hold First Quarter Financial Results Conference Call on May 14, 2015 at 5:00 PM EDT May 13 2015
Transgenomic to Hold First Quarter Financial Results Conference Call on May 14, 2015 at 5:00PM EDT May 13 2015
Transgenomic to incorporate Horizon Discovery’s Genomic Reference Standards into Multiplexed ICE... Apr 26 2015
Transgenomic to Incorporate Horizon Discovery's Genomic Reference Standards into Multiplexed ICE... Apr 23 2015
Transgenomic to Incorporate Horizon Discovery's Genomic Reference Standards into Multiplexed ICE... Apr 23 2015
10-K for Transgenomic, Inc. Apr 22 2015
Transgenomic Launches New Multiplexed Ice-Cold PCR Service in Biomarker Identification Business Apr 20 2015
Transgenomic Launches New Multiplexed ICE-COLD PCR™ Service in Biomarker Identification Business Apr 20 2015
TRANSGENOMIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 15 2015
Transgenomic Provides Financial and Business Update Apr 15 2015
Transgenomic Announces Business and Financial Update Conference Call on April 15, 2015 at 5:00 PM... Apr 14 2015
Transgenomic Announces Business and Financial Update Conference Call on April 15, 2015 at 5:00 PM... Apr 14 2015
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Apr 02 2015
Transgenomic Expands License Agreement with Exiqon to Support Global Commercialization of its... Mar 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK